EU Approves New First-Line Therapy for HER2-Positive Metastatic Breast Cancer
The European Commission has approved Enhertu in combination with pertuzumab as a first-line treatment for adults with unresectable or metastatic HER2-positive breast cancer. This marks the first new regimen for this indication in over a decade, demonstrating a 44% reduction in disease progression or death in the DESTINY-Breast09 trial. This approval offers a significant new therapeutic option for patients.